Loading provider…
Loading provider…
Medical Oncology Physician in Duarte, CA
NPI: 1184987166Primary Employer
City of Hope Medical - San Bernardino Radiation Oncology
cityofhope.org
HQ Phone
Get MD Yan's Phone Numberphone_androidMobile
Get MD Yan's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
CA State Medical License
CA State Medical License
2018 - 2026
TX State Medical License
2017 - 2025

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology
Sun Yat-Sen University of Medical Science
Medical School
Until 1994
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 186 | 622 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 61 | 61 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 22 | 38 |
| 4 | 99497Advance care planning by the physician or other qualified health care professional | 20 | 23 |
Reduction of seed motion using a bio-absorbable polymer coating during permanent prostate brachytherapy using a mick applicator technique.
Authors: Rodney Ellis, Bryan Traughber
Publication Date: 2017-08-15
Authors: Chen, Weihsu C, Yuan, Julie S, Xing, Yan, Mitchell, Amanda, Mbong, Nathan, Popescu, Andreea C, McLeod, Jessica, Gerhard, Gitte, Kennedy, James A, Bogdanoski, Goce, Lauriault, Stevan, Perdu, Sofie, Merkulova, Yulia, Minden, Mark D, Hogge, Donna E, Guidos, Cynthia, Dick, John E, Wang, Jean C Y
Journal: Cancer Res
Publication Date: 2016-02-01
Combined inhibition of the phosphoinosityl-3-kinase (PI3Kinase) P110δ subunit and mitogen-extracellular activated protein kinase (MEKinase) shows synergistic cytotoxicity against human acute myeloid leukemia progenitors.
Authors: Yan Xing, Donna Hogge
Publication Date: 2012-10-09
Lead Sponsor: AbbVie
Intervention / Treatment: DRUG: Osimertinib, DRUG: Nivolumab, DRUG: Erlotinib, DRUG: Telisotuzumab vedotin